That's a good little snippet there. They do a nice job making the arithmetic understandable. The thing that is rarely pointed out, but probably well known here, is Absolute Risk Reduction (ARR) - and those numbers are tiny and probably not even statistically significant. My understanding is that it is uncommon for a clinical trial to only have 1% of people catching the disease in the first place, so while the ongoing trials are big they are not so big as to deduce statistical significance of 1% reduction in endpoint over a short period of time (say a couple-three weeks).
It looks like there is more of this video - I don't see its title on the LR link.
That's a good little snippet there. They do a nice job making the arithmetic understandable. The thing that is rarely pointed out, but probably well known here, is Absolute Risk Reduction (ARR) - and those numbers are tiny and probably not even statistically significant. My understanding is that it is uncommon for a clinical trial to only have 1% of people catching the disease in the first place, so while the ongoing trials are big they are not so big as to deduce statistical significance of 1% reduction in endpoint over a short period of time (say a couple-three weeks).
It looks like there is more of this video - I don't see its title on the LR link.
(post is archived)